Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study

Inclusion Criteria: * 18-75 years of age, males or non-pregnant females; * With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction; * Total number of target lesion is 1; * Target lesion must be ≤ 25mm in length (visual estimation) and 3.0 to 3.75 mm in diameter ; * Visual assessment of target lesion diameter stenosis ≥ 70%,TIMI blood flow≥1; * The target lesion can be covered by one stent; * Patient must be an acceptable candidate for coronary artery bypass graft; * To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. Exclusion Criteria: * Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal; * Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months; * Severe congestive heart failure (NYHA class III and above) ,left ventricular ejection fraction or \<40% (ultrasound or left ventricular angiography); * Preoperative renal function serum creatinine \>2.0mg/DL; receiving hemodialysis; * Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; * Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; * The patient's life expectancy is less than 12 months; * To participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; * Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; * Heart transplantation patients; * The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia; * Cancer need chemotherapy; * Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy; * Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc; * Within six months for elective surgery requires stopping aspirin, Clopidogrel patients; * Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis); * Peripheral vascular disease, 6F catheter is not available.